Mesoblast Investor Relations Material
Latest events
H2 2025
Mesoblast
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mesoblast Limited
Access all reports
Mesoblast Limited is an Australian biotechnology company that develops cellular medicines based on mesenchymal lineage cells. The company’s pipeline targets inflammatory and cardiovascular diseases, with therapies in various stages of clinical development. Its operations include research, regulatory affairs, and strategic licensing. Mesoblast Limited is headquartered in Melbourne, Australia, and its shares are listed on the ASX.
Key slides for Mesoblast Limited
H2 2025
Mesoblast Limited
H2 2025
Mesoblast Limited
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
MSB
Country
🇦🇺 Australia